Status:
UNKNOWN
The Study of Warfarin Maintenance Dose in Chinese Patients
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital
Conditions:
Atrial Fibrillation
Heart Valve Disease
Eligibility:
All Genders
18+ years
Brief Summary
1. Title: Clinical study of the relationship between Pharmacogenomics and warfarin dose in Chinese patients 2. Drug: Warfarin 3. Design: To value the accuracy of warfarin Pharmacogenomics algorithm by...
Detailed Description
* For the patients who need to use warfarin, detect the "Vitamin K epoxide reductase complex subunit 1 (VKORC1),cytochrome p450 2C9 (CYP2C9), and cytochrome p450 4F2 (CYP4F2) genotype. * Record the de...
Eligibility Criteria
Inclusion
- Chinese patients
- Age \>18y
- target INR 1.5\~3.0
- Patients signed informed consent
Exclusion
- Has hemorrhage disease, or tendency to significant bleeding
- Severe liver and kidney disfunction, serious infections, severe heart failure (NYHA heart function classification Ⅲ magnitude), severe pulmonary hypertension, abnormal thyroid function, respiratory failure, anemia, malignant tumor, blood disease
- patients with pregnancy or lactation;
- with cognitive impairment.
Key Trial Info
Start Date :
June 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2014
Estimated Enrollment :
1000 Patients enrolled
Trial Details
Trial ID
NCT01855737
Start Date
June 1 2013
End Date
January 1 2014
Last Update
June 4 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Key Laboratory of Clinical Trial Research in Cardiovascular Drugs, Ministry of Health, Cardiovascular Institute and Fuwai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College
Beijing, China, 100037